9精品在线,人操中文字幕的,久久伊人精美视频

Competitive Landscape of Autoimmune Drug Development: Trends & Innovations Market Trend Explore the competitive landscape of autoimmune drug development, focusing on innovative therapies, treatment models, and global R&D trends driving progress in immune modulation and B cell depletion.
AkzoNobel India's Revenue and Business Sale Plans Market Trend AkzoNobel India's revenue for FY 2025 grew to INR 40.91B, with a 3% increase. The company plans to sell its decorative paint business and undergoes strategic evaluations for long-term growth.
Nippon Paints's Q1 2025 Financial report Market Trend Nippon Paint reports 2.6834 Billion dollars Q1 revenue in FY2025, with China retail up 5% and net profit rising 13%. Despite a slight dip in China revenue, profits surged due to cost controls and volume growth.
Asian Paints's Q1 2025 Financial report Market Trend Discover the fascinating story behind the discovery of #streptomycin and its impact on #tuberculosis treatment. Explore the clash between mentor and student, #Waksman and #Schatz, and the legacy of this groundbreaking antibiotic.
Dr. Reddy's Q1 2025 Financial report Market Trend Dr. Reddy's FY2024 revenue rose 17% to $3.81B, driven by strong generics, strategic acquisitions, and a focus on OTC and healthcare. Net profit grew 2.8% as the company expanded globally.
Takeda Shuts Down EGFR, B7-H3 Programs Takeda Takeda announces major R&D cuts, discontinuing EGFR and B7-H3 oncology projects from its $525M Maverick deal, and streamlining other pipelines to focus on high-potential therapies.
Takeda's 2024 Q4 Financial report Market Trend Takeda's 2024 fiscal report shows 7.4% revenue growth to ￥4.58T, driven by strong core business and R&D breakthroughs. Key segments include GI, rare diseases, oncology. Outlook for 2025 remains stable despite VYVANSE competition.
Axalta's Q1 2025 Financial report Market Trend Axalta reported Q1 2025 revenue of $1.262 billion, down 2.5% YoY, with strong 17% growth in China driven by surging auto production. Net income rose 154% to $99M amid cost improvements.
BeiGene's Q1 2025 Financial report Market Trend BeiGene's Q1 2025 report highlights a 50.2% revenue growth, with zanubrutinib sales exceeding 5 billion RMB and achieving its first quarterly profit under US GAAP. The company also advances its oncology pipeline globally.
Novo Nordisk's Q1 2025 Financial report Market Trend Novo Nordisk's Q1 2025 revenue surged 18% to $11.9B, driven by diabetes and obesity treatments. Wegovy sales soared 83%, while semaglutide products contributed 71% of total revenue.

< Pre 1...18 19 202122 23 24...26 Next >

Articles Archives

Hot Articles

All Categories

Agri & Industry Cosmetic Laboratory Pharmaceutical Food

国产91视频久久,亚洲综合色图在线观看,五月天操逼网,日韩色色AV,青青在线A片,亚洲最大色在线观看,欧美熟妇丝袜诱惑,青青操逼视频,日韩无码操出水